3 completed, 1 withdrawn. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Hydroxychloroquine (HCQ): new trials by email Literature Review of Hydroxychloroquine (HCQ) trials Research Report on Hydroxychloroquine (HCQ)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") Hydroxychloroquine (HCQ), Gedatolisib - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2019-02-26 | 2020-04-28 | |
| Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day - Advanced BRAF Mutant Melanoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 50 | 2014-10-01 | 2022-01-20 |
| A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Hydroxychloroquine (HCQ), Vemurafenib (VEM) - Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 8 | 2013-06-01 | 2020-05-29 |
| A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer Hydroxychloroquine (HCQ), Gemcitabine, Abraxane - Advanced Adenocarcinoma, Metastatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 119 | 2011-12-01 | 2025-07-25 |
Adenocarcinoma (1) · Breast Neoplasms (1) · Melanoma (1)
Abramson Cancer Center at Penn Medicine (4)
United States (4)
Ravi Amaravadi, MD (2) · Angela DeMichele, MD (1) · Peter O'Dwyer, MD (1)